Abstracts tagged "Nephritis and treatment"

Abstract Number: 2091 • 2018 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Atsushi Nomura³, Hirofumi Amano¹, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake^4,5, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, ⁴Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, ⁵Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 719 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis in Isolation or Accompanied By Extra-Renal Manifestations: Early Lessons from the Accelerating Medicines Partnership
Judith A. James¹, Michelle Petri², Chaim Putterman³, Betty Diamond⁴, David Wofsy⁵, Chun Hao Lee⁶, Derek Fine⁶, Anna R. Broder⁷, Robert M. Clancy⁸, Peter M. Izmirly⁹, Michael Belmont¹⁰, Nicole Bornkamp¹¹, Anne Davidson¹², Patti Tosta¹³, Kenneth C. Kalunian¹⁴, Meyeon Park¹⁵, Maria Dall'Era¹⁶, Richard Furie¹⁷, Elena Massarotti¹⁸, German T. Hernandez¹⁹, Fernanda Payan-Schober²⁰, Sean M. Connery¹⁹, Diane L. Kamen²¹, Iris Lee²², William Pendergraft III²³, Jennifer H. Anolik²⁴, Ummara Shah²⁵, Soumya Raychaudhuri²⁶, Yvonne C. Lee²⁷, Joel M. Guthridge²⁸, V. Michael Holers²⁹, Paul J. Utz³⁰, Mina Pichavant³¹, Rohit Gupta³¹, Holden T. Maecker³², Michael Weisman³³ and Jill P. Buyon³⁴, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁴Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Rheumatology, UCSF, San Francisco, CA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Albert Einstein College of Medicine, Bronx, NY, ⁸NYU School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰New York University, NYC, NY, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹³Immune Tolerance Network, San Francisco, CA, ¹⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ¹⁵University of California San Francisco, San Francisco, CA, ¹⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹⁷Hofstra Northwell, Manhasset, NY, ¹⁸Brigham and Women's Hospital, Boston, MA, ¹⁹Texas Tech University HSC El Paso, El Paso, TX, ²⁰Texas Tech University HSC El Paso, El Paso, TX, ²¹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²²Temple University Hospital, Philadelphia, PA, ²³Kidney Center, University of North Carolina, Chapel Hill, NC, ²⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²⁵Division of Rheumatology, New York University School of Medicine, NYC, NY, ²⁶Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ²⁹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ³⁰Medicine, Stanford University School of Medicine, Stanford, CA, ³¹Stanford University, Stanford, CA, ³²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³³Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ³⁴Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) remains one of the most serious complications of SLE, occurring in up to 50% of patients. Current LN treatments are not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].